Cargando…
Corrigendum to: Brigatinib dose rationale in anaplastic lymphoma kinase–positive non‐small cell lung cancer: Exposure–response analyses of pivotal ALTA study
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452300/ https://www.ncbi.nlm.nih.gov/pubmed/34414680 http://dx.doi.org/10.1002/psp4.12698 |
| _version_ | 1784570037522137088 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8452300 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84523002021-09-27 Corrigendum to: Brigatinib dose rationale in anaplastic lymphoma kinase–positive non‐small cell lung cancer: Exposure–response analyses of pivotal ALTA study CPT Pharmacometrics Syst Pharmacol Corrigendum John Wiley and Sons Inc. 2021-08-19 2021-09 /pmc/articles/PMC8452300/ /pubmed/34414680 http://dx.doi.org/10.1002/psp4.12698 Text en © 2021 The Authors. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Corrigendum Corrigendum to: Brigatinib dose rationale in anaplastic lymphoma kinase–positive non‐small cell lung cancer: Exposure–response analyses of pivotal ALTA study |
| title | Corrigendum to: Brigatinib dose rationale in anaplastic lymphoma kinase–positive non‐small cell lung cancer: Exposure–response analyses of pivotal ALTA study |
| title_full | Corrigendum to: Brigatinib dose rationale in anaplastic lymphoma kinase–positive non‐small cell lung cancer: Exposure–response analyses of pivotal ALTA study |
| title_fullStr | Corrigendum to: Brigatinib dose rationale in anaplastic lymphoma kinase–positive non‐small cell lung cancer: Exposure–response analyses of pivotal ALTA study |
| title_full_unstemmed | Corrigendum to: Brigatinib dose rationale in anaplastic lymphoma kinase–positive non‐small cell lung cancer: Exposure–response analyses of pivotal ALTA study |
| title_short | Corrigendum to: Brigatinib dose rationale in anaplastic lymphoma kinase–positive non‐small cell lung cancer: Exposure–response analyses of pivotal ALTA study |
| title_sort | corrigendum to: brigatinib dose rationale in anaplastic lymphoma kinase–positive non‐small cell lung cancer: exposure–response analyses of pivotal alta study |
| topic | Corrigendum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452300/ https://www.ncbi.nlm.nih.gov/pubmed/34414680 http://dx.doi.org/10.1002/psp4.12698 |